Disappointing PhIII results dash AstraZeneca's hopes of reviving a tarnished cancer drug through Lynparza combo
Barely a year after a team at Yale tried to make sense of some unexpected Phase II results around an ovarian cancer drug that AstraZeneca had all but shelved, Phase III investigators are reporting that it might all have been a mirage.
Despite the elevated expectations, adding cediranib to Lynparza — AstraZeneca’s Merck-partnered star PARP inhibitor — did not improve progression-free survival compared to platinum-based chemotherapy. The GY004 trial recruited patients with platinum-sensitive relapsed ovarian cancer.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 92,600+ biopharma pros reading Endpoints daily — and it's free.